Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy

Transplantation

Volumn 90, Issue 5, 2010, Pages 502-509

  Kers, Jesper ^a,b   Xu Dubois, Yi Chun ^b,c   Rondeau, Eric ^b,c   Claessen, Nike ^a   Idu, Mirza M ^a   Roelofs, Joris J T H ^a   Bemelman, Fréderike J ^a   Ten Berge, Ineke J M ^a   Florquin, Sandrine ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b INSERM   (France)

^c HÔPITAL TENON   (France)

Author keywords

Biomarkers; CD44; Chronic allograft dysfunction; Epithelial to mesenchymal transition; Kidney transplantation; Vimentin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD44V ANTIGEN; VIMENTIN; HERMES ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN EXPRESSION; ARTICLE; ATROPHY; CLINICAL ARTICLE; FEMALE; GLOMERULUS FILTRATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TUBULAR ATROPHY; TUBULAR DYSFUNCTION; ALLOTRANSPLANTATION; BIOPSY; BLOOD; FIBROSIS; GENETICS; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; ATROPHY; BIOPSY; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIMENTIN; YOUNG ADULT;

EID: 77957273572     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e86b42     Document Type: Article

References (60)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. Schweitzer EJ, Matas AJ, Gillingham KJ, et al. Causes of renal allograft loss. Progressinthe 1980s, challenges for the 1990s. Ann Surg1991; 214: 679.
3. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56: 783.
4. Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplantation 2002; 74: 149.
5. mus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
6. Yilmaz S, Isik I, Afrouzian M, et al. Evaluating the accuracy of functional biomarkers for detecting histological changesinchronic allograft nephropathy. Transpl Int 2007; 20: 608.
7. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584.
8. KaplanB,Schold J,Meier-Kriesche HU. Poor predictive valueof serum creatinine for renal allograft loss. Am J Transplant 2003; 3: 1560.
9. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341.
10. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420.
11. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119: 1417.
12. AcloqueH,Adams MS, Fishwick K,et al. Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 2009; 119: 1438.
13. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429.
14. Vongwiwatana A, Tasanarong A, Rayner DC, et al. Epithelial to mesenchy-mal transition during late deterioration of human kidney transplants: The role of tubular cells in fibrogenesis. Am J Transplant 2005; 5: 1367.
15. Marhaba R, Zoller M. CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 2004; 35: 211.
16. Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003; 46: 165.
17. Jothy S. CD44 and its partners in metastasis. Clin Exp Metastasis 2003; 20: 195.
18. Pure E, Cuff CA. A crucial role for CD44 in inflammation. Trends Mol Med 2001; 7: 213.
19. Naor D, Nedvetzki S, Assayag N, et al. The mechanism of molecular redundancy in autoimmune inflammation in the context of CD44 deficiency. Ann N Y Acad Sci 2005; 1050: 52.
20. Heldin P, Karousou E, Bernert B, et al. Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis. Connect Tissue Res 2008; 49: 215.
21. Siegelman MH, DeGrendele HC, Estess P. Activation and interaction of CD44 and hyaluronan in immunological systems. J Leukoc Biol 1999; 66: 315.
22. Roy-Chaudhury P, Khong TF, Williams JH, et al. CD44 in glomerulo-nephritis: Expression in human renal biopsies, the Thy 1.1 model, and by cultured mesangial cells. Kidney Int 1996; 50: 272.
23. Gueler F, Gwinner W, Schwarz A, et al. Long-term effects of acute ischemia and reperfusion injury. Kidney Int 2004; 66: 523.
24. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998; 66: 1697.
25. Rouschop KM, Roelofs JJ, Claessen N, et al. Protection against renal ischemia reperfusion injury by CD44 disruption. J Am Soc Nephrol 2005; 16: 2034.
26. Rouschop KM, Sewnath ME, Claessen N, et al. CD44 deficiency increases tubular damage but reduces renal fibrosis in obstructive ne-phropathy. J Am Soc Nephrol 2004; 15: 674.
27. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of postglo-merular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996; 19: 191.
28. Rouschop KM, Claessen N, Pals ST, et al. CD44 disruption prevents degeneration of the capillary network in obstructive nephropathy via reduction of TGF-beta1-induced apoptosis. J Am Soc Nephrol 2006; 17: 746.
29. Qiaoling Z, Xiaoyun J, Wei W, et al. Altered P-selectin and CD44 expression in the renal tissues and peripheral blood of children with IgA nephropathy. Int Urol Nephrol 2009; 41: 703.
30. Florquin S, Nunziata R, Claessen N, et al. CD44 expression in IgA nephropathy. Am J Kidney Dis 2002; 39: 407.
31. Nakamura H, Kitazawa K, Honda H, et al. Roles of and correlation between alpha-smooth muscle actin, CD44, hyaluronic acid and os-teopontin in crescent formation in human glomerulonephritis. Clin Nephrol 2005; 64: 401.
32. Kirimca F, Sarioglu S, Camsari T, et al. Expression of CD44 and major histocompatibility complex class II antigens correlate with renal scarring in primary and systemic renal diseases. Scand J Urol Nephrol 2001; 35: 509.
33. Daniel L, Sichez H, Giorgi R, et al. Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int 2001; 60: 2215.
34. Sarioglu S, Sis B, Tuncer C, et al. Tubular CD44 expression in renal allograft biopsies. Transplant Proc 2004; 36: 92.
35. Rouschop KM, Roelofs JJ, Sylva M, et al. Renal expression of CD44 correlates with acute renal allograft rejection. Kidney Int 2006; 70:1127.
36. Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 2006; 17: 305.
37. Solez K, Colvin RB, Racusen LC, et al. Banff'05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
38. Hertig A, Verine J, Mougenot B, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006; 6: 2937.
39. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, et al. Epithelial-to- mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol 2008; 19: 1571.
40. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
41. Kupin W, Nakhleh R, Lee M, et al. Separate risk factors for the development of transplant glomerulopathy vs chronic tubulointerstitial rejection. Transplant Proc 1997; 29: 245.
42. Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805.
43. Marcussen N, Olsen TS, Benediktsson H, et al. Reproducibility of the Banff classification of renal allograft pathology. Inter-and intraob-server variation. Transplantation 1995; 60: 1083.
44. Ishimura T, Fujisawa M, Isotani S, et al. Transforming growth factor-beta1 expression in early biopsy specimen predicts long-term graft function following pediatric renal transplantation. Clin Transplant 2001; 15: 185.
45. Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004; 13: 279.
46. Cheng O, Thuillier R, Sampson E, et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006; 6: 2292.
47. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886.
48. Jonker M, Danskine A, Haanstra K, et al. The autoimmune response to vimentin after renal transplantation in nonhuman primates is immu-nosuppression dependent. Transplantation 2005; 80: 385.
49. Weiss L, Slavin S, Reich S, et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc Natl Acad Sci USA 2000; 97: 285.
50. Jones M, Tussey L, Athanasou N, et al. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem 2000; 275: 7964.
51. van der Voort R, Taher TE, Wielenga VJ, et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 1999; 274: 6499.
52. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563.
53. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010; 140: 798.
54. Tripepi G, Jager KJ, Dekker FW, et al. Diagnostic methods 2: Receiver operating characteristic (ROC) curves. Kidney Int 2009; 76: 252.
55. Sund S, Grimm P, Reisaeter AV, et al. Computerized image analysis vs semiquantitative scoring in evaluation of kidney allograft fibrosis and prognosis. Nephrol Dial Transplant 2004; 19: 2838.
56. Nicholson ML, Harper SJ, Wheatley TJ, et al. Renal transplant fibrosis: Histomorphometric assessment of early renal transplant biopsies for markers of chronic rejection. Transplant Proc 1997; 29: 2793.
57. Pape L, Henne T, Offner G, et al. Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: A new tool for predicting long-term graft function.Transplantation2003; 76: 955.
58. Nankivell BJ, Chapman JR, Gruenewald SM. Detection of chronic al-lograft nephropathy by quantitative doppler imaging. Transplantation 2002; 74: 90.
59. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515.
60. Nickerson P, Jeffery J, Gough J, et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years post-transplant. J Am Soc Nephrol 1998; 9: 482.